Boswellia serrata is one of the most researched botanical ingredients used in modern joint-support supplements. Standardized Boswellia extracts have been evaluated in randomized human trials for knee-related pain, stiffness, physical function and mobility, and several studies have reported meaningful improvements compared with placebo.
The most important detail is not simply whether a supplement contains “Boswellia.” The extract, standardization, dose and study population all matter. This guide explains what Boswellia is, what the strongest human evidence shows, how to read a Boswellia label, and where it fits in a broader joint-support routine.
Key Takeaways
- Human evidence exists: randomized controlled trials have reported improvements in pain, stiffness, walking ability and physical function with standardized Boswellia serrata extracts.
- A 2020 meta-analysis of seven randomized trials involving 545 participants found significant improvements in pain, stiffness and joint-function measures versus control groups.
- Standardization matters: some trials used extracts standardized to specific boswellic acids such as AKBA, while other supplements list total boswellic acids. These are not automatically interchangeable.
- There is no single universal “Boswellia dose”: clinical trials have used different proprietary extracts and doses, so milligrams should be interpreted together with extract composition.
- Safety has generally been favorable in trials: the U.S. National Center for Complementary and Integrative Health (NCCIH) notes that Boswellia serrata extract has been used safely in clinical studies at doses up to 1,000 mg daily for as long as six months.
What Is Boswellia Serrata?
Boswellia serrata is a tree whose gum resin has a long history of use in traditional Ayurvedic practice. The resin is also associated with frankincense, although modern supplements generally use concentrated Boswellia extracts rather than raw resin.
According to the U.S. National Center for Complementary and Integrative Health, oral Boswellia products are commonly marketed for joint health and mobility, and several human studies have reported benefits for osteoarthritis-related pain and inflammation. NCCIH also notes that larger, higher-quality trials are still needed.
What Are Boswellic Acids?
Boswellic acids are a family of naturally occurring compounds found in Boswellia resin. They are commonly used to standardize Boswellia extracts so the amount of key plant constituents is more consistent from serving to serving.
One of the best-known compounds is 3-O-acetyl-11-keto-beta-boswellic acid (AKBA). Laboratory research suggests that boswellic acids can influence inflammatory signaling pathways, including 5-lipoxygenase activity. That mechanism is scientifically interesting, but the more useful evidence for a consumer comes from controlled human trials measuring outcomes such as pain, stiffness and physical function.
What Does the Human Research Show?
A 2020 meta-analysis found improvements in pain, stiffness and joint function
A systematic review and meta-analysis published in BMC Complementary Medicine and Therapies analyzed seven randomized controlled trials involving 545 participants with osteoarthritis.
Compared with control groups, Boswellia and Boswellia extracts were associated with significant improvements across several outcomes:
- Visual Analog Scale pain: weighted mean difference -8.33
- WOMAC pain: -14.22
- WOMAC stiffness: -10.04
- WOMAC physical function: -10.75
- Lequesne functional index: -2.27
The review concluded that Boswellia extracts showed promising effects for pain, stiffness and function, while also noting substantial differences between formulations and limitations in the size and quality of the underlying trials. Read the meta-analysis on PubMed.
A classic randomized trial reported better pain, knee flexion and walking distance
One of the earlier placebo-controlled trials enrolled 30 people with knee osteoarthritis in a randomized, double-blind crossover design. Participants received Boswellia serrata extract or placebo for eight weeks before crossing over.
The Boswellia phase produced significant improvements in knee pain, knee flexion and walking distance compared with placebo. The extract was generally well tolerated, with minor gastrointestinal effects reported in some participants. See the 2003 randomized trial on PubMed.
A 90-day trial of a high-AKBA extract improved multiple knee-function measures
A 2008 randomized, double-blind, placebo-controlled trial evaluated a proprietary Boswellia extract standardized to 30% AKBA. Seventy-five participants received either 100 mg, 250 mg or placebo daily for 90 days.
The researchers evaluated pain and physical function using VAS, WOMAC and the Lequesne Functional Index. Both active groups improved on several measures, with the study reporting earlier responses in the higher-dose group. Read the trial on PubMed.
A 120-day study found improvements in pain, stiffness and physical function
A 2019 randomized, double-blind, placebo-controlled pilot trial included 48 adults with knee osteoarthritis. Participants received a standardized Boswellia extract for 120 days or placebo.
The Boswellia group showed significant improvements in physical function, pain and stiffness, and no serious adverse events were reported. The authors also reported changes in hs-CRP and radiographic measures.
This trial is useful, but its commercial context matters: all authors were affiliated with Sami Labs or Sabinsa Corporation, which held patents or trademarks related to the extract studied. That does not invalidate the findings, but it is relevant when weighing the evidence. Review the 2019 trial and conflict-of-interest statement on PubMed.
A 2024 multicenter trial reported improvements in mobility and function over 90 days
A more recent randomized, double-blind, placebo-controlled trial enrolled 105 participants and compared placebo with two doses of a Boswellia extract standardized to 30% AKBA. Participants received either 150 mg or 300 mg twice daily for 90 days.
Ninety-eight participants completed the study. By day 90, the authors reported large improvements from baseline in VAS pain, WOMAC total score, WOMAC pain, stiffness and function, along with better six-minute walking distance in both Boswellia groups. Between-group differences versus placebo became significant on several outcomes later in the study.
The trial adds useful newer evidence, although several authors were affiliated with Sami-Sabinsa Group or Sabinsa Corporation, the companies associated with the proprietary extract. Read the 2024 trial on PubMed.
A 2025 randomized trial adds more recent evidence
A 2025 randomized, double-blind, placebo-controlled study evaluated a standardized Boswellia serrata extract in 150 adults aged 40 to 75 with non-to-mild knee osteoarthritis over 90 days.
The Boswellia group showed significant improvements in total WOMAC scores at days 30, 60 and 90, with additional improvements in pain, stiffness, function and Lequesne scores. The study also reported reductions in inflammatory biomarkers. No meaningful safety signal emerged during the trial.
Several authors were affiliated with companies involved in botanical ingredient development, so the findings are best interpreted alongside the broader evidence base rather than in isolation. Read the 2025 randomized trial on PubMed.
Why the Type of Boswellia Extract Matters
Two bottles can both say “Boswellia serrata” and still contain materially different extracts.
Clinical studies have used preparations standardized in different ways, including:
- specific percentages of AKBA;
- total beta-boswellic acids;
- total boswellic acids;
- proprietary delivery systems designed to change absorption.
This matters because 100 mg of one standardized extract is not automatically equivalent to 100 mg of another. When comparing supplements, look for the botanical species, plant part, extract amount and standardization rather than relying only on the ingredient name.
What Dose of Boswellia Has Been Studied?
There is no single dose that can be applied across every Boswellia extract. Human trials have used a broad range, including approximately 100 to 600 mg per day of different standardized extracts, while some studies have used higher amounts.
The 2020 meta-analysis noted that several included trials used approximately 100–250 mg of standardized Boswellia preparations, but the authors emphasized that formulation differences and study quality make direct dose comparisons difficult.
For that reason, the most useful approach is to compare a product's exact extract and standardization with the preparation used in the research rather than judging a formula on milligrams alone.
How Long Does Boswellia Take to Work?
Most joint studies have evaluated Boswellia over several weeks to several months. The 2020 meta-analysis found evidence of improvements after at least four weeks in several trials, while some proprietary-extract studies reported earlier changes.
Those timelines describe study groups, not a guaranteed personal response. Joint-support supplements are generally better evaluated as part of a consistent routine rather than by expecting a specific result after a fixed number of days.
What to Look for in a Boswellia Supplement
- Boswellia serrata identified by species. “Frankincense” alone is less specific.
- The extract amount per full serving. Check the actual serving size, not just the amount per capsule.
- Standardization. A label that states total boswellic acids, AKBA or another defined constituent gives you more information about what the extract contains.
- Transparent formulation. Multi-ingredient products should disclose the amount of each active rather than hide the formula in a proprietary blend.
- Context of the research. Match the extract on the label to the extract used in human studies whenever possible.
How Boswellia Fits With MSM and Glucosamine
Boswellia, MSM and glucosamine are often grouped together in joint-support formulas, but they are not redundant ingredients.
MSM has randomized human evidence for knee-related physical function and symptom scores. Glucosamine has a long research history in joint-health studies, with results depending partly on the specific glucosamine form. Boswellia contributes a botanical component with controlled-trial and meta-analytic evidence for pain, stiffness and physical function.
For a deeper comparison of the other major ingredients in this category, read our guide to MSM & Glucosamine for Joint Support: Benefits, Clinical Evidence & How They Work.
Safety and Tolerability
Boswellia has generally been well tolerated in human trials. NCCIH states that Boswellia serrata extract has been used safely in studies at doses up to 1,000 mg per day for as long as six months, and at 2,400 mg per day for up to one month. Review the NCCIH safety summary.
Research on medicinal-dose Boswellia during pregnancy and breastfeeding is limited. If you are pregnant, nursing, have a medical condition or take prescription medication, discuss a new herbal supplement with a qualified healthcare professional before use.
Frequently Asked Questions
Is Boswellia the same as frankincense?
Boswellia resin is the botanical source of frankincense. Dietary supplements usually contain a concentrated Boswellia extract rather than the aromatic resin used for incense or essential oils.
What are boswellic acids?
Boswellic acids are naturally occurring triterpenes found in Boswellia resin. Supplement extracts are often standardized to a specified percentage of boswellic acids or a particular compound such as AKBA.
Is a higher percentage of boswellic acids always better?
Not necessarily. A higher percentage tells you that the extract is more concentrated in the constituent being measured, but clinical relevance depends on the exact extract, dose, bioavailability and human evidence behind that preparation.
Can Boswellia be taken with MSM and glucosamine?
These ingredients are commonly combined in joint-support formulas because they play different roles in the formulation. The finished formula, serving amounts, other botanicals and any medications you use should still be considered together.
Does Boswellia work immediately?
Clinical trials generally evaluate outcomes over weeks rather than hours. Some proprietary-extract studies have reported early changes, but the broader evidence is better viewed as support for consistent use over time rather than a guaranteed rapid effect.
The Bottom Line
Boswellia serrata has meaningful human clinical evidence behind its use in joint-support supplements. Randomized trials and a meta-analysis have reported improvements in pain, stiffness and physical-function measures, making Boswellia one of the more evidence-backed botanical ingredients in the joint category.
The most important buying decision is not simply “Does this contain Boswellia?” It is whether the label identifies the extract, amount and standardization clearly enough to understand what you are taking.
Explore a Transparent Joint-Support Formula
If you are comparing joint-support formulas, start with our Movement & Mobility collection. FlexiCore™ combines a Boswellia serrata extract standardized to 65% boswellic acids with MSM, plant-derived GlucosaGreen® glucosamine HCl, turmeric, hyaluronic acid and complementary ingredients in a fully disclosed formula.
You can review the complete Supplement Facts and directions for FlexiCore™ here. The ingredient studies discussed in this article are not clinical trials of the finished FlexiCore™ formula.
References
- Yu G, et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020. PMID: 32680575. DOI: 10.1186/s12906-020-02985-6.
- Kimmatkar N, et al. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee—randomized double blind placebo controlled trial. Phytomedicine. 2003. PMID: 12622457. DOI: 10.1078/094471103321648593.
- Sengupta K, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. 2008. PMID: 18667054.
- Majeed M, et al. A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytother Res. 2019. PMID: 30838706. DOI: 10.1002/ptr.6338.
- Majeed A, et al. A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days—a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial. Front Pharmacol. 2024. PMID: 39092235. DOI: 10.3389/fphar.2024.1428440.
- Jayaram M, et al. Clinical Benefits of Boswellia Serrata (BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study. J Med Food. 2025. PMID: 41220252. DOI: 10.1177/1096620X251392467.
- National Center for Complementary and Integrative Health. Boswellia: Usefulness and Safety. Updated April 2025.
This article is for educational purposes and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the U.S. Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease. Consult a qualified healthcare professional before beginning a new supplement if you take prescription medication, have a medical condition, or are pregnant or breastfeeding.